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INTRODUCTION
Urothelial carcinoma (UC) is the fourth most common malig-
nancy in men and the ninth most common in women, ac-
counting for estimated new cases of 330400 and estimated 
death of 123100 patients worldwide in 2012.1 There are two 
distinct subtypes in UC: superficial disease and muscle inva-
sive disease.2,3 Almost 80% of patients with UC are initially di-
agnosed with superficial disease which is potentially curable 
by transurethral resection. Nevertheless, the majority of them 
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Key Words:  Urinary bladder neoplasms, receptor tyrosine kinases, prognosis, cystectomy
Yonsei Med J 2016 Jul;57(4):831-839
http://dx.doi.org/10.3349/ymj.2016.57.4.831
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: June 9, 2015   Revised: October 22, 2015
Accepted: October 23, 2015
Corresponding author: Dr. Sun Young Rha, Division of Medical Oncology, De-
partment of Internal Medicine, Yonsei University College of Medicine, 50-1 Yon-
sei-ro, Seodaemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-8050, Fax: 82-2-362-5592, E-mail: rha7655@yuhs.ac
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2016
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
http://dx.doi.org/10.3349/ymj.2016.57.4.831832
FGFR1, a Prognostic Factor in Muscle Invasive Urothelial Carcinoma
experience one or more recurrences, and 25% will eventually 
develop muscle invasive disease. Although the standard treat-
ment of muscle invasive disease is radical cystectomy, the ma-
jority of treatment failure is systemic relapse with distant metas-
tases.4 Since gemcitabine plus cisplatin demonstrated equivalent 
efficacy with superior tolerability compared to methotrexate, 
vinblastine, doxorubicin, and cisplatin in randomized phase 
III trial, it has become the standard treatment of advanced or 
metastatic UC.5 However, there is no standard therapeutic op-
tion after failure of cisplatin-based first line chemotherapy, 
which rendered the overall survival (OS) of patients with ad-
vanced UC less than 2 years. Thus, there is clearly unmet need 
to identify molecular markers and to develop more effective 
therapeutic strategy for UC.
Human epidermal growth factor-2 receptors (HER2) play 
crucial role in signal transduction pathways regarding cell pro-
liferation, survival, angiogenesis, and metastasis. Since trastu-
zumab, a recombinant humanized monoclonal antibody tar-
geted to the extracellular domain of HER2 have dramatically 
changed the treatment of HER2 amplified breast cancer and 
gastric cancer,6-8 there is emerging interest to apply this thera-
peutic strategy to other malignancies. Although HER2 ampli-
fication and overexpression were found in UCs, there exists 
higher variability ranging from 23% to 80% for over-expression 
and from 0% to 32% for amplification.9,10 In addition, its role as 
a prognostic marker in muscle invasive UC still remains con-
troversial.11-14
Fibroblast growth factor receptors (FGFRs) play a key role 
in the regulation of proliferation, differentiation, and apopto-
sis.15 Recently, it has become clear that there exists FGF signal-
ing alteration in a substantial proportion of bladder tumors.16 
Mutation of FGFR3, the most common genetic alteration in 
superficial UC, results in constitutive activation of the recep-
tor,17 and it is strongly associated with low tumor grade and 
stage.18 While increased expression of FGFR3 was found in the 
majority (about 85%) of FGFR3-mutant superficial tumors, it 
may also be achieved via overexpression of the wild-type re-
ceptor.18 Muscle invasive bladder tumors have been found to 
overexpress wild type FGFR3 protein, as well.18 These results 
suggest a potential role of mutant FGFR3 predominantly in 
superficial UC and overexpression of wild-type FGFR3 in in-
vasive UC. Preclinical studies using small molecule inhibitor 
against FGFR showed the possibility of FGFR3 as a useful 
therapeutic target in UC.19 Although relatively little is known 
about the role of other FGFRs in UC, FGFR1 expression is 
known to be increased in the majority of bladder cancer cell 
lines regardless of tumor stage and grade,20 and increased 
FGFR1 expression induces increased proliferation and cell 
survival.20 However, there has been no data regarding the 
prognostic role of FGFR1 and FGFR3 overexpression in pa-
tients with muscle invasive UC after radical cystectomy.
Hence, the aim of this study is to examine the usefulness of 
HER2, FGFR1, and FGFR3 expression as prognostic markers 
and therapeutic targets in muscle invasive UC patients. In ad-
dition, we investigated the correlations between these recep-
tor tyrosine kinases (RTKs) and various clinico-pathological 
factors.
MATERIALS AND METHODS
Patients
We retrospectively analyzed the data of 98 patients who un-
derwent radical cystectomy for muscle invasive UC of the uri-
nary bladder from 2005 to 2010 at a single institute, Yonsei 
Cancer Center. We included patients whose archival tissue 
samples from cystectomy specimen were available, and tu-
mor histology should be confirmed as UC. Patients were ex-
cluded if they receive neoadjuvant chemotherapy before they 
underwent radical cystectomy. All patients underwent radical 
cystectomy and bilateral pelvic lymphadenectomy. Surgical 
procedures consisted of an en-bloc radical cystectomy with 
para-aortic lymph node dissection (PLND) and urinary diver-
sion. PLND included the internal and external iliac and obtu-
rator lymph nodes. Tumors were restaged according to the 
American Joint Commmitee on Cancer/International Union 
against Cancer staging system 7th edition.21 World Health Or-
ganization reference center system was used for tumor grading.
This study received the approval of Institutional Review Board 
and was conducted in accordance with the Helsinki Declara-
tion of 1975.
Immunohistochemical analysis
For immunohistochemistry (IHC) analysis, formalin-fixed 
paraffin-embedded tissue containing the representatives of 
each tumor were prepared and sectioned as slides with 5-um 
thickness. Slides were stained with the monoclonal antibod-
ies: FGFR1 (Rabbit Anti-Human FGFR-1 polyclonal antibody, 
SPRING, Pleasanton, CA, USA), FGFR3 [FGFR-3 (B-9), Santa 
Cruz, Dallas, TX, USA], and HER2 (polyclonal rabbit anti-hu-
man c-erbB-2 oncoprotein, DAKO, Glostrup, Denmark) via 
standard IHC as previously described.18
The level of HER2 protein expression was assessed by the 
intensity and percentage of staining and scored on a scale of 0 
to 3+.9 The evaluation was performed only on the invasive com-
ponent of the tumor. A score of 1+ was defined as barely percep-
tible membrane staining in more than 10% of cells, a score 2+ 
was defined as weak-to-moderate complete membrane stain-
ing present in more than 10% of tumor cells, and a score 3+ 
was defined as strong complete membrane staining in more 
than 30% of tumor cells. A cytoplasmic staining was consid-
ered nonspecific. Tumors presenting 2+ or 3+ HER2 expres-
sion were considered to have HER2 overexpression.
A semi-quantitiative scoring system was adopted: 0, all tu-
mor cells negative; 1, faint but detectable positivity in some or 
all cells; 2, weak but extensive positivity; 3, strong positivity.18 
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As there is yet no established method for the assessment for 
FGFR1 or FGFR3 positivity, we defined FGFR1 and FGFR3 
positive if they have cytoplasmic immune-reactivity regard-
less of the staining intensity (Fig. 1). Immunostaining was as-
sessed by two independent pathologists who were blinded to 
clinical outcomes.
Statistical analysis
OS was calculated from the date of cystectomy to death of any 
cause. Time to recurrence (TTR) was defined as the duration 
from cystectomy to the date of first documented recurrence. 
Patients who were still alive at the cut off day were censored at 
the date of last contact.
The association between clinico-pathological parameters 
was evaluated using Student’s t-test (for numerical variables) 
or Pearson’s chi-square test (for categorized variables). Kar-
plan-Meier curves were plotted for TTR and OS, and the dif-
ference of survival time was analyzed using log-rank test. Multi-
variate survival analysis was performed with Cox’s proportional 
regression hazard model. p values <0.05 were used as signifi-
cant level. All analyses were performed with SPSS program, 
version 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
The baseline characteristics of the patients are described in Ta-
ble 1. The median age was 69.5 years (range, 41–88 years), with 
82 male and 16 female patients. Sixty four patients (65.3%) had 
muscle invasive disease as initial manifestation, whereas 34 
patients (34.7%) were initially diagnosed with non-invasive 
disease, treated by transurethral resection of tumor one or 
more times, but ultimately developed muscle invasive disease.
Regarding pathologic stage after cystectomy, 23 patients 
(23.5%) were diagnosed with tumor confined to muscularis pro-
pria layer (T2) and tumor invasion beyond that (T3, T4) was 
observed in 75 patients (76.5%). Node involvement was found 
Fig. 1. Immunohistochemistry staining (×200) of urothelial carcinoma showing different grades of FGFR1 expression. (A) Negative. (B) Moderate signaling 
in 30% of cells. (C) Weak signaling in 70% of cells. (D) Moderate signaling in 70% of cells. FGFR1, fibroblast growth factor receptor 1.
A
C
B
D
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in 36 patients (36.7%). Overall, 58 patients (59.2%) were diag-
nosed with stage II or III disease, and 40 patients (40.8%) had 
stage IV disease. All the tumors were assessed as high grade tu-
mor. After cystectomy, adjuvant chemotherapy was given to 47 
patients (48.0%).
There were 41 (41.8%), 44 (44.9%), and 14 (14.2%) patients 
who had over-expressed HER2, FGFR1, and FGFR3, respec-
tively (Fig. 2, Table 1). While 28 patients (28.6%) had none of 
them, 70 patients (71.4%) had at least one receptor expression 
among the three receptors. There were 19 patients who had 
over-expression of both HER2 and FGFR1, 5 patients in HER2 
and FGFR3, and 8 patients in FGFR1 and FGFR3. Over-ex-
pression of all three receptors was found only in three patients.
Survival analysis according to receptor status
With a median follow-up duration of 34.3 months (range 1–117 
months), there has been 54 (55.1%) recurrences and 67 (67.7%) 
deaths. Median TTR and median OS of whole population was 
18.2 months [95% confidence interval (CI): 12.8–23.5] and 
37.3 months (95% CI: 21.7–52.9), respectively.
We performed univariate analysis of TTR and OS according 
to receptor status and other clinical parameters (Table 2). Sig-
nificantly shorter median TTR was seen in female patients 
(compared to male, 7.5 months vs. 19.7 months; p=0.029), he-
moglobin (Hb) ≤12.0 g/dL (compared to Hb >12.0 g/dL, 15.3 
months vs. 30.9 months; p=0.021), lymph node positive (LN+) 
disease (compared to LN-disease, 15.1 months vs. 60.8 months; 
p=0.002), lympho-vascular invasion (compared to LVI-, 13.5 
months vs. 38.4 months; p= 0.002), and non-invasive disease as 
an initial manifestation (compared to initial invasive disease, 
15.1 months vs. 23.3 months; p= 0.027).
Regarding the receptor status, patients with FGFR1 overex-
pression had worse TTR than those without FGFR1 expression 
(12.9 months vs. 49.0 months; p=0.008) (Fig. 3A). By contrast, 
there was no difference in TTR according to HER2 and FGFR3 
receptor status as well as age, previous adjuvant chemotherapy.
Similar results were found in univariate analysis for OS; fe-
male patients (compared to male, 11.2 months vs. 40.5 months; 
p=0.021), non-invasive disease as initial manifestation com-
pared to invasive disease (19.1 months vs. 48.7 months; p= 
0.026), Hb ≤12.0 g/dL (compared to >12 g/dL, 26.5 months vs. 
48.9 months; p=0.029), dissected lymph node number ≤12 (com-
pared to >12, 19.3 months vs. 52.7 months; p=0.005) and FGFR1 
overexpression (22.3 months vs. 52.7 months; p=0.006) showed 
significantly worse survival (Fig. 3B).
In multivariate analysis (Table 3), FGFR1 and non-invasive 
disease as initial manifestation remained as significant prog-
nostic factors for TTR with hazard ratio of 2.04 (95% CI: 1.27–
3.90, p=0.018) and 2.10 (95% CI: 1.28–4.17, p=0.008), respec-
tively. Also, they were significant prognostic factor for OS with 
hazard ratio of 2.23 (95% CI: 1.27–3.90, p=0.006) and 1.80 (95% 
CI: 1.28–4.17, p=0.038), respectively.
We also examined whether there are any interactions of each 
receptor status with survival. In patients without FGFR1 expres-
Table 1. Baseline Characteristics of Patients
Variables n=98 %
Age, yrs  
Median (range) 69.5 (41–88)
Sex
Male 82 83.7
Female 16 16.3
Initial manifestation
Noninvasive 34 34.7
Invasive 64 65.3
T stage
pT2 23 23.5
pT3 or pT4 75 76.5
Node
Negative 62 63.3
Positive 36 36.7
Grade
Low 0 0
High 98 100
HER2 IHC
Negative (0–1+) 57 58.2
Positive (2–3+) 41 41.8
FGFR1
Negative 54 55.1
Positive 44 44.9
FGFR3
Negative 84 85.7
Positive 14 14.3
Adjuvant chemotherapy
No 51 52.0
Yes 47 48.0
HER2, human epidermal growth factor receptor 2; FGFR, fibroblast growth 
factor receptor; IHC, immunohistochemistry.
Fig. 2. Distribution of patients according to the HER2 and FGFR expression 
status. HER2, human epidermal growth factor receptor 2; FGFR, fibroblast 
growth factor receptor.
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sion, HER2 overexpression had a tendency for shorter TTR (16.7 
months vs. not reached; p=0.085) and OS (42.7 months vs. 76.3 
months; p=0.172). Interestingly, among patients with FGFR1 ex-
pression, HER2 overexpression showed longer TTR (15.3 
months vs. 12.9 months; p=0.208) and OS (28.6 months vs. 20.2 
months; p=0.142) without statistical significance.
Clinico-pathologic characteristics of FGFR1, 3, and 
HER2 receptor status
Table 4 shows significant difference in the frequency of FGFR1 
expression between gender; FGFR1 overexpression was found 
in 75% (12 out of 16) of female patients, whereas in only 39% (32 
out of 50) of male patients (p=0.008). Also, FGFR1 overexpres-
sion was found more frequently in node positive patients than 
in node negative patients (61.1% vs. 35.5%; p=0.014). Conse-
quently, it is more frequently found in stage IV than stage II or 
III patients (57.9% vs. 36.7%; p=0.040). Otherwise, there was no 
significant association in other variables according to recep-
tor status.
Table 2. Univariate Analysis for TTR and OS
Variables n Median TTR (95% CI) p value Median OS (95% CI) p value
Overall 98 18.2 (12.8–23.5) 37.3 (21.7–52.9)
Age 0.332 0.187
≤70 54 16.7 (10.6–22.7) 39.4 (28.9–49.8)
>70 44 21.4 (4.5–38.3) 27.4 (0.0–59.1)
Sex 0.029 0.021
Male 82 19.7 (13.3–26.1) 40.5 (21.6–59.4)
Female 16 7.5 (0.0–16.7) 11.2 (9.1–13.3)
Initial manifestation 0.027 0.026
Non-invasive 34 15.1 (6.2–24.0) 19.1 (2.2–36.0)
Invasive 64 23.3 (3.4–43.3) 48.7 (30.5–66.9)
Hb 0.021 0.029
≤12.0 59 15.3 (5.5–25.2) 26.5 (15.8–37.1)
>12.0 39 30.9 (NA) 48.9 (21.9–75.9)
pT stage 0.062 0.138
T2 23 Not reached 49.5 (26.8–72.1)
T3–4 75 16.1 (12.8–23.5) 29.5 (12.8–46.3)
pN stage 0.002 0.231
Node negative 62 68.0 (NA) 48.9 (23.3–74.5)
Node positive 36 15.1 (10.6–19.5) 26.6 (20.9–32.3)
LVI 0.002  0.006
No 63 38.4 (NA) 49.5 (30.5–68.4)
Yes 35 13.5 (3.9–23.1) 24.8 (12.9–36.6)
LN number dissected 0.153  0.005
≤12 43 11.4 (2.0–20.9) 19.3 (7.3–31.3)
>12 55 20.4 (3.4–37.4) 52.7 (31.6–73.8)
HER2 0.388  0.828
(-) 57 30.9 (4.4–57.5) 37.3 (12.0–62.6)
(+) 41 16.7 (4.0–24.6) 37.3 (18.5–56.2)
FGFR1 0.008  0.006
(-) 54 49.0 (0.0–102.5) 52.7 (30.8–74.7)
(+) 44 12.9 (2.6–23.2) 22.3 (14.5–30.0)
FGFR3 0.532  0.302
(-) 84 19.7 (12.5–27.0) 37.3 (19.2–55.4)
(+) 14 15.3 (5.8–24.9) 24.8 (0.0–50.2)
Adjuvant chemotherapy 0.751 0.711
Yes 47 17.7 (12.2–23.2) 37.3 (23.2–51.4)
No 51 20.4 (4.6–36.1) 42.6 (13.0–72.3)
TTR, time to recurrence; OS, overall survival; CI, confidence interval; Hb, hemoglobin; LVI, lymphovascular invasion; LN, lymph nodes; HER2, human epidermal 
growth factor receptor 2; FGFR, fibroblast growth factor receptor.
http://dx.doi.org/10.3349/ymj.2016.57.4.831836
FGFR1, a Prognostic Factor in Muscle Invasive Urothelial Carcinoma
DISCUSSION
We investigated the prognostic role of three different RTKs in 
the survival of the patients who underwent radical cystectomy 
for muscle invasive UC, and found that FGFR1 was a strong 
prognostic factor, whereas HER2 and FGFR3 did not show any 
prognostic impact. Although the association of activating mu-
tations and over-expression of FGFR3 with a lower risk of pro-
gression and better survival in superficial UC have been well 
known,16 we herein first demonstrated the prognostic impor-
tance of FGFR1 in muscle invasive UC.
Recently, a lot of interest have been focused on FGFR path-
way as a therapeutic target in UC because of earlier preclinical 
studies19 and the development of new drugs targeting FGFR 
pathway. Several clinical trials to investigate the efficacy of FGFR 
inhibitors in UC as single drug (NCT00790426, NCT01732107) 
or in combination with cytotoxic agents (NCT01496534) are 
underway. Currently, however, it is not known whether FGFRs 
have prognostic impact in muscle invasive UC. Our present 
study, first demonstrated that overexpression of FGFR1, but 
not FGFR3 or HER2, is a worse prognostic factor in muscle in-
vasive UC: the prognostic impact of FGFR1 was sustained even 
after adjustment of other prognostic factors such as patholog-
ic stage, lympho-vascular invasion, number of dissected lymph 
nodes, or Hb level before cystectomy.
One of important issues to be addressed is how to identify 
target population who can benefit the most from FGFR target-
ing drugs. Urothelial cancer cell lines with overexpression of 
FGFR1 or 3 respond to FGFR inhibitors more efficiently than 
cell lines with mutation of those receptors.19 To date, fluores-
cent in situ hybridization (FISH) or silver in situ hybridization 
has generally been used as detection methods for FGFR am-
plification in gastric cancer, breast cancer, and non-small cell 
lung cancer.22-24 In the present study, however, we used IHC, 
one of the most available and inexpensive tools. The previous 
research showed low proportion of tumors showing FGFR1 
amplification in UC which could not explain the high fre-
quency of increased expression. This discrepancy suggests 
Fig. 3. Survival curves according to FGFR1 expression level. (A) Progression free survival. (B) Overall survival. FGFR1, fibroblast growth factor receptor 1.
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Table 3. Multivariate Analysis for TTR and OS
Variables HR for recurrence p value HR for death p value
FGFR1 (+) vs. (-) 2.04 0.018 2.23 0.006
Female vs. male 1.60 0.182 1.59 0.153
Non-inv. vs. Inv. 2.10 0.008 1.80 0.038
Hb ≤12.0 g/dL vs. >12.0 g/dL 1.61 0.112 1.32 0.312
pT3–4 vs. pT2 1.54 0.243 1.26 0.470
pN+ vs. pN- 1.72 0.072 0.84 0.541
LVI+ vs. LVI- 1.39 0.321 1.67 0.064
Dissected nodes >12 vs. ≤12 0.71 0.214 0.51 0.283
TTR, time to recurrence; OS, overall survival; HR, hazard ratio; FGFR1, fibroblast growth factor receptor 1; Inv., invasive disease as initial manifestation; Non-inv., 
non-invasive disease as initial manifestation; LVI, lymphovascular invasion.
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that FGFR1 overexpression might result from post-transcrip-
tional regulation such as altered splicing or increased tran-
script stability rather than dependent only on gene amplifica-
tion.25 Thus, we hypothesized that IHC which detects the final 
protein product could be a suitable method for the detection of 
FGFR1 overexpression in UC. Since we showed the prognostic 
role of FGFR1 overexpression assessed by IHC, IHC would be 
considered relevant technique to detect FGFR1 overexpres-
sion, at least in muscle invasive UC. However, further research-
es on true incidence of FGFR1 amplification (assessed by 
FISH) and the concordance rate between IHC and FISH are 
warranted to identify proper biomarker. Also, it needs to be 
validated in clinical trials targeting UC patients.
It was of an interest to observe significant difference in the 
frequency of FGFR1 over-expression tumors according to 
gender (female 75% vs. male 39%). In addition, female pa-
tients had significantly worse TTR and OS than male patients. 
The fact that it lost its prognostic impact after adjustment by 
other variables, including FGFR1, suggests that the worse sur-
vival outcome in female patients might be due to higher pro-
portion of FGFR1 overexpression. Although this finding should 
be validated in a large, different cohort, it might help us to iden-
tify a subset of patient population who are more likely to have 
FGFR1 overexpression and benefit from therapeutic approach 
targeted to this molecular aberration, as female predominance 
of epidermal growth factor receptor mutation in non-small 
cell lung cancer did.
HER2 overexpression was observed in 41 out of 98 patients 
(41.8%), which was in the range reported in previous works. 
The high variability of HER2 overexpression incidence and its 
prognostic role can be explained by small numbers of patients 
in each study and also by heterogeneity of laboratory tests 
used. To overcome such limitations, the assessment of HER2 
status needs to be standardized in terms of antibodies and in-
terpretation of the results. In this study, HER2 overexpression 
did not show any difference on the survival of patients with 
muscle invasive UC after radical cystectomy. Interestingly, our 
result suggested that patients with HER2 overexpression tend-
ed to have better or worse survival outcome with or without 
FGFR1 receptor expression, respectively. Although the surviv-
al difference was not statistically significant, the discrepancies 
on the prognostic value of HER2 overexpression in UC, re-
ported in previous articles, might be due to heterogeneity of 
FGFR1 status which was not checked in the previous works. If 
this is the case, UC patients could be stratified to four different 
categories according to HER2 and FGFR receptor status. How-
Table 4. Patient Characteristics According to Receptor Tyrosine Kinase
Variables
FGFR1 FGFR3 HER2
+ (n=44) - (n=54) p value + (n=14) - (n=84) p value + (n=41) - (n=57) p value 
Age, yrs 0.942 0.620
Median (range) 69 (44–88) 71 (41–87)  72 (44–87) 69 (41–88) 0.201 70 (41–80) 69 (42–88)  
Sex 0.008 0.577 0.348
Male 32 (39.0) 50 (61.0)  11 (13.4) 71 (86.6)  36 (43.9) 46 (56.1)  
Female 12 (75.0) 4 (25.0) 3 (18.8) 13 (81.2) 5 (31.2) 11 (68.8)
Initial manifestation 0.589 0.231 0.339
Noninvasive 14 (41.2) 20 (58.8)  7 (20.6) 27 (79.4)  12 (35.3) 22 (64.7)  
Invasive 30 (46.9) 34 (53.1) 7 (10.9) 57 (89.1) 29 (45.3) 35 (54.7)
T stage 0.876 0.064 0.251
T2 10 (43.5) 13 (56.5)  6 (26.1) 17 (73.9)  12 (52.2) 11 (47.8)  
T3–4 34 (45.3) 41 (54.7) 8 (10.7) 67 (89.3) 29 (38.7) 46 (61.3)
Node 0.014 0.494 0.094
Negative 22 (35.5) 40 (64.5)  10 (16.1) 52 (83.9)  22 (35.5) 40 (64.5)  
Positive 22 (61.1) 14 (38.9) 4 (11.1) 32 (88.9) 19 (52.8) 17 (47.2)
Overall stage 0.040 0.352 0.706
II–III 22 (36.7) 38 (63.3)  7 (11.7) 53 (88.3)  26 (43.3) 34 (56.7)  
IV 22 (57.9) 16 (42.1) 7 (18.4) 31 (81.6) 15 (39.5) 23 (60.5)
Metastatic lesion 
Lung 6 (50.0) 6 (50.0) 3 (25.0) 9 (75.0) 4 (33.3) 8 (66.7)
Bone 11 (73.3) 4 (26.7) 2 (13.3) 13 (86.7) 9 (60.0) 6 (40.0)
Liver 5 (62.5) 3 (37.5) 2 (25.0) 6 (75.0) 6 (75.0) 2 (25.0)
Lymph node 21 (65.6) 11 (34.4) 5 (15.6) 27 (84.4) 15 (46.9) 17 (53.1)
Brain 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
Carcinomatosis 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0)
FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2.
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ever, one should be cautious to accept this hypothesis until it 
is validated in subsequent trials.
We hypothesized that there might be survival differences 
between muscle invasive tumors as initial presentation and 
initial superficial tumors in which muscle invasion developed 
later on. Notably, significant difference in both TTR and OS 
was seen between two groups. This finding might result from 
distinct pathophysiology at molecular level between two groups, 
or it might have simply been derived from treatment related 
effect. Although this results suggest that initial manifestation 
should be considered as important prognostic factor in pa-
tients who underwent radical cystectomy for muscle invasive 
UC, one should be cautious because we defined non-invasive 
disease based on pathologic finding after transurethral resec-
tion of bladder, a procedure with an inherent limitation for true 
pathologic staging. Further analysis of the treatment course 
may explain such disparity of outcome, however, we did not 
perform such analysis because substantial proportion of pa-
tients were diagnosed and treated with superficial disease be-
fore being transferred to the study hospital, or they were diag-
nosed a long time before cystectomy that we could obtain the 
medical record.
This study has several limitations, largely due to its retro-
spective nature. First, this study was conducted at a single cen-
ter with a small number of patients. Thus, it is hard to general-
ize the results to an entire patient cohort. Second, because this 
study was based on retrospective chart review, there might be 
significant selection bias. Third, even though treatment was 
administered largely based on guidelines, there were some 
differences in treatment protocols and follow up strategies, 
such as interval at which follow-up CT scan was performed.
In conclusion, we showed that overexpression of FGFR1, 
but not FGFR3, assessed by IHC is strongly associated with 
disease recurrence and worse OS in muscle invasive UC pa-
tients who received radical cystectomy. Since it is found in a 
high proportion of invasive tumors and there are commer-
cially available drugs targeted to this pathway, it should be 
considered as an important therapeutic target in future treat-
ment strategy.
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